Robert A Hauser
Overview
Explore the profile of Robert A Hauser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
6254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Sep;
13(6):1747-1749.
PMID: 39266813
No abstract available.
2.
Isaacson S, Dewey R, Hauser R, Kremens D, Kumar R, Lew M, et al.
Clin Park Relat Disord
. 2024 Aug;
11:100264.
PMID: 39175580
Introduction: In the United States (US), prophylactic treatment with the antiemetic trimethobenzamide has been used before initiating apomorphine therapy. However, US trimethobenzamide stores have been depleted, leaving uncertainty regarding whether...
3.
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B, et al.
Brain
. 2024 Aug;
147(8):2652-2667.
PMID: 39087914
Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has...
4.
Aradi S, Hauser R
Expert Rev Neurother
. 2024 Jul;
24(8):787-797.
PMID: 39049547
Introduction: Cervical dystonia (CD) causes involuntary movements and postures of the head, neck, and shoulders, as well as nonmotor symptoms including pain, mood, and sleep dysfunction, and impacts quality of...
5.
Hauser R, Barkay H, Fernandez H, Jimenez-Shahed J, Factor S, Gross N, et al.
J Clin Psychopharmacol
. 2024 Jun;
44(4):386-396.
PMID: 38901008
Background: Deutetrabenazine is approved for adults with tardive dyskinesia (TD). Data based on underlying psychiatric condition and baseline dopamine receptor antagonist (DRA) use are limited. Methods: Patients with TD who...
6.
Hauser R, Videnovic A, Soares-da-Silva P, Liang G, Olson K, Jen E, et al.
Parkinsonism Relat Disord
. 2024 Apr;
123:106971.
PMID: 38631081
Introduction: In BIPARK-1 and BIPARK-2, addition of once-daily opicapone to levodopa/carbidopa significantly reduced daily "OFF"-time relative to placebo in adults with Parkinson's disease (PD) and motor fluctuations. Diary data from...
7.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Apr;
13(3):655-675.
PMID: 38557959
Introduction: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual...
8.
Fung V, Aldred J, Arroyo M, Bergquist F, Boon A, Bouchard M, et al.
Clin Park Relat Disord
. 2024 Feb;
10:100239.
PMID: 38419617
Background: As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous...
9.
Comella C, Jankovic J, Hauser R, Patel A, Banach M, Ehler E, et al.
Neurology
. 2024 Jan;
102(4):e208091.
PMID: 38295339
Background And Objectives: ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety of 2 doses of DaxibotulinumtoxinA for Injection (DAXI), a...
10.
Trosch R, Comella C, Caroff S, Ondo W, Shillington A, LaChappelle B, et al.
J Clin Psychiatry
. 2024 Jan;
85(1).
PMID: 38270545
Current clinician-rated tardive dyskinesia (TD) symptom scales have not addressed the expanding clinical signs and functional impact of TD. The study objective was to develop and test the reliability of...